- May 31, 2022
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy. Sponsor Arcellx, Inc Collaborator Multiple Myeloma Research Foundation ClinicalTrials.gov Identifier: NCT05396885 Official Title: A Phase II Study of CART-
223
- May 26, 2022
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant. Sponsor Memorial Sloan Kettering Cancer Center ClinicalTrials.gov Identif
117
- May 16, 2022
#COMY22 - Myeloma Abstracts - COMy World Congress Paris, France - May 12-15, 22
The 8th COMy World Congress – Paris, France & Online, May 12 - 15, 2022 #COMY 22 - MYELOMA ABSTRACTS The 8th COMy World Congress – Paris, France & Online The 8th World Congress on. Controversies in Multiple Myeloma (COMy) May 12-15, 2022. Online medical congress. https://comylive.cme-congresses.com/ Relapsed Refractory Multiple Myeloma Newly Diagnosed Multiple Myeloma
234
- May 15, 2022
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
IMF Patient & Family Webinar - New Frontiers In Myeloma Care, May 14, 2022 You are central to the care team: Be Empowered Watch Video on IMF Website: IMF Patient & Family Webinar - New Frontiers In Myeloma Care https://www.myeloma.org/videos/imf-patient-family-webinar-new-frontiers-myeloma-care List Prior IMF Patient &Family Webinars Click here Learn more: https://www.myeloma.org/publications https://www.youtube.com/c/IMFMyeloma/videos https://www.myeloma.org
127
- May 14, 2022
The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma
The ESMO Virtual Plenaries The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma Learn more: https://www.esmo.org/meetings/about-esmo-meetings https://www.esmo.org/meetings/esmo-virtual-plenaries
57
- May 12, 2022
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma The purpose of this study is to
116
- May 9, 2022
International Academy for Clinical Hematology (IACH) Journal Club - May 17, 2022 - 07:00 PM Paris
International Academy for Clinical Hematology (IACH) Journal Club May 17, 2022 07:00 PM Paris Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk https://clinical-hematology.org/iach-journal-club/
97
- May 7, 2022
PE: CDC Guidelines: How to prevent infections (Sepsis) while getting chemotherapy?
PE: CDC Guidelines - How to prevent infections (sepsis) while getting chemotherapy? Information for Patients and Caregivers | Preventing Infections in Cancer Patients | CDC People with cancer who are treated with chemotherapy are more likely to get infections because of their weakened immune system. Cancer and chemotherapy can damage your immune system, reducing your numbers of infection-fighting white blood cells and making it harder for your body to fight infections. An inf
580